Xenetic Biosciences, Inc. (NASDAQ:XBIO) Shares Shorted: Short Interest Up 237.7% in October

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 37,018 shares, a growth of 237.7% from the October 15th total of 10,961 shares. Approximately 1.7% of the company’s shares are short sold. Based on an average trading volume of 31,416 shares, the short-interest ratio is currently 1.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has a consensus rating of “Sell”.

Xenetic Biosciences Trading Up 3.9%

XBIO stock opened at $1.87 on Thursday. The company has a market cap of $4.28 million, a PE ratio of -1.61 and a beta of 2.36. The stock has a 50-day moving average price of $2.53 and a two-hundred day moving average price of $2.82. Xenetic Biosciences has a 12-month low of $1.58 and a 12-month high of $4.94.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for oncology indications. The company’s primary focus is its XCART platform, an autologous cell-therapy technology designed to modify a patient’s own T cells to recognize and attack cancer cells. Xenetic has applied the XCART platform to potential treatments for B-cell malignancies, including programs intended to target specific antigens found on cancerous B cells. The company’s research and development activities have centered on advancing personalized immunotherapies through preclinical and clinical development.